• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Patients With Small-Cell Lung Cancer Face Barriers to Combined-Modality Therapy

Article

While chemotherapy with thoracic radiation has been established as the standard of care for the initial treatment of non-metastatic small-cell lung cancer, a large proportion of patients do not receive these treatments and in turn have lower overall survival, according to a study published in JAMA Oncology.

A large percentage of patients with non-metastatic small-cell lung cancer (SCLC) face substantial barriers to standard-of-care therapy and in turn have lower overall survival, according to research from The University of Texas MD Anderson Cancer Center, which was published in JAMA Oncology.

“Approximately 15% to 30% of lung cancers are SCLC, and one-third of cases are diagnosed in the limited stage (LS),” wrote the authors. They continued, “For LS-SCLC, initial management with concurrent chemotherapy and thoracic radiation therapy is the standard of care in the United States.”

The authors analyzed initial management of all LS-SCLC cases from 2004 to 2013 in the National Cancer Database (NCDB). A total of 70,247 patients were included, and their baseline characteristics were determined; 55.3% of patients were women. The initial treatment was 55.5% chemotherapy and radiation, 20.5% chemotherapy alone, 3.5% radiation therapy alone, 20% neither chemotherapy nor radiation therapy, and 0.5% not reported.

There was a median follow-up of 62.3 (95% Cl, 62.3-64.1) months, and survival was compared between the groups. Results showed that patients who received chemotherapy and radiation had significantly better median survival (18.2 months; 95% Cl, 17.9-18.4 months) than any other group (P <.001). Patients who received chemotherapy or radiation therapy alone had a median survival of 10.5 (95% Cl, 10.3-10.7) and 8.3 (95% Cl, 7.7-8.8) months, respectively. The group of patients who received neither chemotherapy nor radiation therapy had worse median survival (3.7 months; 95% Cl, 3.5-3.8 months) when compared with any other group.

The authors also found that a patient’s lack of insurance (odds ratio [OR], 0.75; 95% Cl, 0.67-0.85; P <.001), coverage through Medicaid (OR, 0.79; 95% CI, 0.72-0.87; P &thinsp;<&thinsp;.001), and coverage through Medicare (OR, 0.86; 95% CI, 0.82-0.91; P &thinsp;<&thinsp;.001) were associated with a decreased likelihood of receiving radiation therapy in comparison with private or managed care insurance. Being uninsured (OR, 0.65; 95% CI, 0.56-0.75; P &thinsp;<&thinsp;.001) was also associated with a lower likelihood of chemotherapy delivery; however, neither Medicaid (OR, 1.01; 95% CI, 0.92-1.10; P &thinsp;=&thinsp;.86) nor Medicare insurance (OR, 0.97; 95% CI, 0.91-1.03; P &thinsp;=&thinsp;.36) was associated with chemotherapy delivery.

Several socioeconomic factors, such as treatment at a non-academic center, lack of health insurance and Medicare or Medicaid coverage were associated with significantly shorter survival.

“Receiving appropriate, evidence-based therapies for limited-stage SCLC is critical, and our findings underscore the need for patients to personally advocate for the standard-of-care treatment for their cancer,” said senior author Stephen G. Chun, MD, assistant professor, Radiation Oncology, University of Texas MD Anderson Cancer Center, in a statement.

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.